What we do

Developing topical non-pharmacological and non-steroidal treatment for skin diseases

Our Company

Aileens Pharma, founded in June 2018, is an Italian biotech company that develops topical non-pharmacological and non-steroidal treatment for skin diseases. Our MISSION is to provide the first safe and effective topical treatment for skin diseases that does not cause the common side effects of medications that are currently available on the market.

Patients with skin diseases – including atopic dermatitis, psoriasis, seborrheic dermatitis and acne – tend to suffer socially and psychologically due to their conditions. Those with mild or moderate forms of skin diseases can often be treated topically, yet most forms are chronic, and the long-term side effects of currently-availably medications (corticosteroids and calcineurin inhibitors) often increase the probability of patients suspending use of these drugs. This is why it is crucial to develop newer, more safer and effective treatments.

Our company’s primary goal is that of filling the current MARKET GAP in PEDIATRIC dermatology, focusing on atopic dermatitis.

The most commonly-used treatments of dermatitis are corticosteroids and immunosuppressants. Yet these treatments are not side effect-free, and patients often stop using them. And the moisturizers that currently-available treatments contain are often too mild and ultimately not effective enough to keep the disease in check.

Our Product

We created LimpiAD as a solution to the lack of non-pharmacological treatment options for atopic dermatitis.

LimpiAD is a skin cream that is created using PATENTED non–photogenic bacteria.

The functional ingredient is based on the cellular wall of non-pathogenic bacteria, conjugated with mucopolysaccharide acting as a carrier. LimpiAD works on a patients’ altered skin microbiota to restore the skin’s natural cutaneous balance (homeostasis), improving the patient’s condition and quality of life.

Our experienced and specialized technicians grow the bacteria and perform the conjugation procedure in our production lab.

Company founder and CEO Sonia Longo Sormani has a strong background in the dermatology sector, where she worked for several years before founding her own company, Claride Pharma. Aileens Pharma is based in Milan and collaborates closely with the Laboratory of Clinical Microbiology, led by Professor Roberto Di Marco from the University of Molise.

Our Company

Aileens Pharma, founded in June 2018, is an Italian biotech company that develops topical non-pharmacological and non-steroidal treatment for skin diseases. Our MISSION is to provide the first safe and effective topical treatment for skin diseases that does not cause the common side effects of medications that are currently available on the market.

Patients with skin diseases – including atopic dermatitis, psoriasis, seborrheic dermatitis and acne – tend to suffer socially and psychologically due to their conditions. Those with mild or moderate forms of skin diseases can often be treated topically, yet most forms are chronic, and the long-term side effects of currently-availably medications (corticosteroids and calcineurin inhibitors) often increase the probability of patients suspending use of these drugs. This is why it is crucial to develop newer, more safer and effective treatments.

Our company’s primary goal is that of filling the current MARKET GAP in PEDIATRIC dermatology, focusing on atopic dermatitis.

The most commonly-used treatments of dermatitis are corticosteroids and immunosuppressants. Yet these treatments are not side effect-free, and patients often stop using them. And the moisturizers that currently-available treatments contain are often too mild and ultimately not effective enough to keep the disease in check.

Our Product

We created LimpiAD as a solution to the lack of non-pharmacological treatment options for atopic dermatitis.

LimpiAD is a skin cream that is created using PATENTED non–photogenic bacteria.

The functional ingredient is based on the cellular wall of non-pathogenic bacteria, conjugated with mucopolysaccharide acting as a carrier. LimpiAD works on a patients’ altered skin microbiota to restore the skin’s natural cutaneous balance (homeostasis), improving the patient’s condition and quality of life.

Our experienced and specialized technicians grow the bacteria and perform the conjugation procedure in our production lab.

Company founder and CEO Sonia Longo Sormani has a strong background in the dermatology sector, where she worked for several years before founding her own company, Claride Pharma. Aileens Pharma is based in Milan and collaborates closely with the Laboratory of Clinical Microbiology, led by Professor Roberto Di Marco from the University of Molise.

Our Partners

Aileens Pharma is financed by two Italian venture capital investors

Panakès Partners

Panakès Partners is a venture capital investor that finances European and Israeli medical companies, early-stage startup, and SMEs that offer extremely promising products and aim to improve patient health and healthcare economics. Investments focus on medical device, diagnostics and healthcare IT fields. Panakès Partners is headquartered in Milan, Italy.

CDP Venture Capital SGR

CDP Venture Capital aims to make venture capital a strategic pillar of Italian economic growth and innovation. It encourages new funds to support startups at all stages of their growth cycle and fosters the evolution of the venture capital system by working
with national agencies and institutions that support startups and by creating a network with leading international players.

Panakès Partners

Panakès Partners is a venture capital investor that finances European and Israeli medical companies, early-stage startup, and SMEs that offer extremely promising products and aim to improve patient health and healthcare economics. Investments focus on medical device, diagnostics and healthcare IT fields. Panakès Partners is headquartered in Milan, Italy.

CDP Venture Capital SGR

CDP Venture Capital aims to make venture capital a strategic pillar of Italian economic growth and innovation. It encourages new funds to support startups at all stages of their growth cycle and fosters the evolution of the venture capital system by working
with national agencies and institutions that support startups and by creating a network with leading international players.